ArticleThe Lancet. Digital health2023
Predicting severe chronic obstructive pulmonary disease exacerbations using quantitative CT: a retrospective model development and external validation study.
Article in The Lancet. Digital health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01969344 (Subpopulations and Intermediate Outcome Measures in COPD Study), which is not on this map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Subpopulations and Intermediate Outcome Measures in COPD Study
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Quantitative computed tomography and predictive modelling for COPD exacerbations.European respiratory review : an official journal of the European Respiratory Society · 2025Pooled it
- A 7-point evidence-based care discharge protocol for patients hospitalized for exacerbation of COPD: consensus strategy and expert recommendation.NPJ primary care respiratory medicine · 2024Pooled it
- Can Quantitative CT Scan Analysis of Pulmonary Parenchymal and Vascular Characteristics Help to Differentiate Among Various Phenotypes of COPD Associated With Pulmonary Hypertension?CHEST pulmonary · 2026Article
- A bibliometric analysis of quantitative computed tomography in chronic obstructive pulmonary disease research based on Web of Science: trends, hotspots, and future directions (2005-2025).Journal of thoracic disease · 2026Article
- Seeing is believing-on the utility of CT in phenotyping chronic obstructive pulmonary disease.The British journal of radiology · 2026Review
- Imaging endpoints for biologic therapy in chronic obstructive pulmonary disease.The British journal of radiology · 2026Review
- Quantitative lung tissue functional analysis for pulmonary adverse event risk assessment prior to thoracic radiotherapy.Physics and imaging in radiation oncology · 2026Article
- Imaging in Chronic Obstructive Pulmonary Disease: Ready for Prime Time?Tuberculosis and respiratory diseases · 2026Article
- Nomogram based on quantitative lung CT features to identify cardiovascular disease in chronic obstructive pulmonary disease and predict prognosis.BMC medical imaging · 2026Article
- Prolonged expiratory time constant and risk of moderate-to-severe exacerbations in stable COPD.Scientific reports · 2026Article
- Innovative Applications and Challenges of Artificial Intelligence in the Whole-Course Management of Chronic Obstructive Pulmonary Disease.International journal of chronic obstructive pulmonary disease · 2026Review
- Association of Lung Quantitative CT Scan Textures With Systemic Inflammation and Mortality in COPD.Chest · 2025Article
- A computed tomography-based lung radiomics nomogram to identify acute exacerbation of chronic obstructive pulmonary disease: a multi-institutional validation study.Journal of thoracic disease · 2025Article
- Toward precision medicine in COPD: phenotypes, endotypes, biomarkers, and treatable traits.Respiratory research · 2025Review
- Cell viability measured by cytotoxicity assay as a biomarker of chronic obstructive pulmonary disease exacerbation: a prospective cohort study.Scientific reports · 2025Article
- Do You Believe in Magic? Computed Tomography, Artificial Intelligence, and Chronic Obstructive Pulmonary Disease.American journal of respiratory and critical care medicine · 2025Article
- The Emerging Biomarkers in Chronic Obstructive Pulmonary Disease: A Narrative Review.Diagnostics (Basel, Switzerland) · 2025Review
- Differentiating Emphysema From Emphysema-Dominated COPD Patients with CT Imaging Feature and Machine Learning.International journal of chronic obstructive pulmonary disease · 2025Article
- Association of Ground-Glass Opacities with Systemic Inflammation and Progression of Emphysema.American journal of respiratory and critical care medicine · 2024Article
- Ground-Glass Opacities on Computed Tomography of the Thorax to Predict Progression of Emphysema: Are We There Yet?American journal of respiratory and critical care medicine · 2024Article
Corrections and comments
- Commented on by
Authors and funding
27 authors at 12 institutions in 1 country.
Funding
Abstract
backgroundQuantitative CT is becoming increasingly common for the characterisation of lung disease; however, its added potential as a clinical tool for predicting severe exacerbations remains understudied. We aimed to develop and validate quantitative CT-based models for predicting severe chronic obstructive pulmonary disease (COPD) exacerbations.
methodsWe analysed the Subpopulations and Intermediate Outcome Measures In COPD Study (SPIROMICS) cohort, a multicentre study done at 12 clinical sites across the USA, of individuals aged 40-80 years from four strata: individuals who never smoked, individuals who smoked but had normal spirometry, individuals who smoked and had mild to moderate COPD, and individuals who smoked and had severe COPD. We used 3-year follow-up data to develop logistic regression classifiers for predicting severe exacerbations. Predictors included age, sex, race, BMI, pulmonary function, exacerbation history, smoking status, respiratory quality of life, and CT-based measures of density gradient texture and airway structure. We externally validated our models in a subset from the Genetic Epidemiology of COPD (COPDGene) cohort. Discriminative model performance was assessed using the area under the receiver operating characteristic curve (AUC), which was also compared with other predictors, including exacerbation history and the BMI, airflow obstruction, dyspnoea, and exercise capacity (BODE) index. We evaluated model calibration using calibration plots and Brier scores.
findingsParticipants in SPIROMICS were enrolled between Nov 12, 2010, and July 31, 2015. Participants in COPDGene were enrolled between Jan 10, 2008, and April 15, 2011. We included 1956 participants from the SPIROMICS cohort who had complete 3-year follow-up data: the mean age of the cohort was 63·1 years (SD 9·2) and 1017 (52%) were men and 939 (48%) were women. Among the 1956 participants, 434 (22%) had a history of at least one severe exacerbation. For the CT-based models, the AUC was 0·854 (95% CI 0·852-0·855) for at least one severe exacerbation within 3 years and 0·931 (0·930-0·933) for consistent exacerbations (defined as ≥1 acute episode in each of the 3 years). Models were well calibrated with low Brier scores (0·121 for at least one severe exacerbation; 0·039 for consistent exacerbations). For the prediction of at least one severe event during 3-year follow-up, AUCs were significantly higher with CT biomarkers (0·854 [0·852-0·855]) than exacerbation history (0·823 [0·822-0·825]) and BODE index 0·812 [0·811-0·814]). 6965 participants were included in the external validation cohort, with a mean age of 60·5 years (SD 8·9). In this cohort, AUC for at least one severe exacerbation was 0·768 (0·767-0·769; Brier score 0·088).
interpretationCT-based prediction models can be used for identification of patients with COPD who are at high risk of severe exacerbations. The newly identified CT biomarkers could potentially enable investigation into underlying disease mechanisms responsible for exacerbations.
fundingNational Institutes of Health and the National Heart, Lung, and Blood Institute.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.